T-cell lymphoma FISH Testing

Key testing

• TLPDF | T-Cell Lymphoma, Diagnostic FISH, Varies
  • When ordered, entire TLP FISH panel will be performed.
• TLPMF | T-Cell Lymphoma, Specified FISH, Varies
  • Probe set(s) to be performed must be specified upon ordering. Any probe set captured under TLPDF can be ordered.
• TLYM | T-Cell Lymphoma, FISH, Tissue
  • Performed on paraffin-embedded tissue. Probe set(s) to be performed based on pathology evaluation, reason for referral, or what is specified upon ordering.
• PATHC | Pathology Consultation
  • Useful for obtaining second opinion on specimens referred by the primary pathologist.

---

T-cell lymphoma next-generation sequencing

When deemed clinically necessary, next-generation sequencing (NGS) can supplement standard-of-care morphology, phenotyping, and FISH testing to refine diagnosis. Our unique MayoComplete T-cell lymphoma panel evaluates 26 genes with known diagnostic, prognostic, or therapeutic value in various T-cell lymphoma subtypes.

While the molecular subclassification of T-cell lymphoma continues to evolve, there are specific patterns of mutation that can be observed in select subtypes, such as angioimmunoblastic T-cell lymphoma (AITL) and large granular lymphocytic leukemia (T-LGL). Recognition of these mutational profiles using the genes provided in our panel can inform on the differential diagnosis of rare or not otherwise specified T-cell lymphomas and guide the selection of a targeted treatment.

Key testing

• NGTCL | MayoComplete T-Cell Lymphoma, Next-Generation Sequencing, Varies
  • Evaluates 26 genes and select intronic regains to aid in establishing the differential diagnosis of various T-cell lymphoma subtypes and resolving complex or atypical presentations.
  • Identifies key mutational profiles in AITL (TET2, DNMT3A, RHOA), T-LGL (STAT3, STAT5B),
  • and other various T-cell lymphomas.
  • Can facilitate diagnosis of TFH lymphoma and support diagnosis of T-cell or NK-cell LGL.
  • Supports physicians in the identification of actionable mutations with a potentially therapeutic target.